Technical Development and Clinical Validation of a Comprehensive One-stop Shop Assessment of the Cirrhotic Liver With [68Ga]Ga-PSMA-11 PET/MRI

Status: Recruiting
Location: See location...
Intervention Type: Drug, Diagnostic test
Study Type: Observational
SUMMARY

A total of fifty-five (55) patients with liver cirrhosis will be enrolled in this study to produce and validate dedicated Ga-PSMA-PET/MRI acquisition protocols. The specific hypotheses include: * Ga-PSMA PET/MRI may allow robust and reproducible noninvasive in vivo quantitation of hepatic macro and microhemodynamics in cirrhotic patients * Dedicated simultaneously acquired DWI sequences might quantitate liver fibrosis and improve hemodynamic quantitation. * Ga-PSMA PET/MRI may allow noninvasive and reproducible quantitation of portal venous hypertension and predict its evolution, as well as response to treatments * Ga-PSMA PET/MRI may improve noninvasive and reproducible qualitative and quantitative assessment of liver function, structure, nodules and predict evolution of cirrhosis

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 99
Healthy Volunteers: f
View:

• Liver cirrhosis as diagnosed by imaging and/or clinical data, including pathology

Locations
United States
Massachusetts
Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School
RECRUITING
Charlestown
Contact Information
Primary
Onofrio Catalano, MD, Ph.D
ocatalano@mgh.harvard.edu
617-724-4030
Backup
Diandrea Galloway
dgalloway@mgh.harvard.edu
617-643-1407
Time Frame
Start Date: 2023-12-10
Estimated Completion Date: 2026-12-19
Participants
Target number of participants: 45
Treatments
Cirrhosis
55 Patients with liver cirrhosis
Sponsors
Leads: Massachusetts General Hospital

This content was sourced from clinicaltrials.gov